Go Pro

Evolent Health (EVH) Stock Price, News & Analysis

Evolent Health logo
$3.59 +0.51 (+16.49%)
Closing price 03:59 PM Eastern
Extended Trading
$3.62 +0.04 (+1.03%)
As of 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Evolent Health Stock (NYSE:EVH)

Advanced

Key Stats

Today's Range
$3.54
$4.15
50-Day Range
$3.05
$6.19
52-Week Range
$2.10
$10.08
Volume
7.07 million shs
Average Volume
3.05 million shs
Market Capitalization
$403.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.16
Consensus Rating
Moderate Buy

Company Overview

Evolent Health, Inc. is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services. Evolent Health’s technology platform integrates claims and clinical data to support risk stratification, predictive modeling and performance reporting. Through its Care Management and Evolent Clinical services, the company deploys teams of nurses, care managers and data analysts to work directly with participating providers and patients, focusing on chronic disease management, preventive care outreach and utilization management.

Evolent Health serves a broad range of geographies across the United States, with key clients spanning commercial, Medicare Advantage and Medicaid populations. The company has collaborated with regional health systems and national insurers to launch accountable care organizations (ACOs), bundled payment programs and total cost-of-care arrangements. By aligning incentives and sharing financial risk, Evolent Health’s partnerships aim to improve patient outcomes while controlling healthcare spending.

Leadership at Evolent Health is headed by Chief Executive Officer Frank Williams, who brings extensive experience in healthcare finance and operations. The management team includes industry veterans in clinical services, technology development and regulatory affairs, reflecting the company’s integrated approach to supporting its clients’ value-based care initiatives.

AI Generated. May Contain Errors.

Evolent Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

EVH MarketRank™: 

Evolent Health scored higher than 72% of companies evaluated by MarketBeat, and ranked 161st out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Evolent Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on no strong buy ratings, 11 buy ratings, 4 hold ratings, and 2 sell ratings.

  • Upside Potential

    Evolent Health has a consensus price target of $6.16, representing about 69.5% upside from its current price of $3.64.

  • Amount of Analyst Coverage

    Evolent Health has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Evolent Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Evolent Health are expected to grow in the coming year, from ($0.16) to $0.08 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Evolent Health is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Evolent Health is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Evolent Health has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Evolent Health's valuation and earnings.
  • Percentage of Shares Shorted

    13.25% of the float of Evolent Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Evolent Health has a short interest ratio ("days to cover") of 6.61.
  • Change versus previous month

    Short interest in Evolent Health has recently decreased by 7.24%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Evolent Health does not currently pay a dividend.

  • Dividend Growth

    Evolent Health does not have a long track record of dividend growth.

  • News Sentiment

    Evolent Health has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Evolent Health this week, compared to 3 articles on an average week.
  • Search Interest

    18 people have searched for EVH on MarketBeat in the last 30 days. This is an increase of 157% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Evolent Health to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Evolent Health insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.48% of the stock of Evolent Health is held by insiders.

  • Percentage Held by Institutions

    Evolent Health has minimal institutional ownership at this time.

  • Read more about Evolent Health's insider trading history.
Receive EVH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolent Health and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EVH Stock News Headlines

Evolent Health (EVH) Q2 2026
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.tc pixel
Evolent Announces Second Quarter 2026 Results
BTIG Remains a Buy on Evolent Health (EVH)
See More Headlines

EVH Stock Analysis - Frequently Asked Questions

Evolent Health's stock was trading at $4.00 at the beginning of 2026. Since then, EVH shares have decreased by 9.1% and is now trading at $3.6350.

Evolent Health, Inc (NYSE:EVH) announced its quarterly earnings data on Thursday, August, 6th. The technology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.01) by $0.03. Evolent Health's revenue was up 46.9% compared to the same quarter last year.
Read the conference call transcript
.

Evolent Health (EVH) raised $172 million in an initial public offering on Friday, June 5th 2015. The company issued 11,500,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health's top institutional investors include Williams & Novak LLC (0.01%). Insiders that own company stock include Seth Blackley, Daniel Joseph Mccarthy, John Paul Johnson, Jonathan Weinberg, Diane Holder, Emily Ann Rafferty and Brendan B Springstubb.
View institutional ownership trends
.

Shares of EVH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evolent Health investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Southern First Bancshares (SFST).

Company Calendar

Today
8/06/2026
Last Earnings
8/06/2026
Next Earnings (Estimated)
8/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Technology
Sub-Industry
Healthcare Technology
Current Symbol
NYSE:EVH
CIK
1628908
Employees
4,200
Year Founded
2011

Price Target and Rating

High Price Target
$10.00
Low Price Target
$3.00
Potential Upside/Downside
+71.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$534.51 million
Net Margins
-26.29%
Pretax Margin
-26.32%
Return on Equity
0.36%
Return on Assets
0.10%

Debt

Debt-to-Equity Ratio
2.46
Current Ratio
1.32
Quick Ratio
1.32

Sales & Book Value

Annual Sales
$1.88 billion
Price / Sales
0.22
Cash Flow
$5.44 per share
Price / Cash Flow
0.66
Book Value
$3.53 per share
Price / Book
1.02

Miscellaneous

Outstanding Shares
112,480,000
Free Float
110,816,000
Market Cap
$403.58 million
Optionable
Optionable
Beta
0.79

Social Links

10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NYSE:EVH) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners